Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2018 Annual Meeting | C193 - Assessment of Rapidly Progressive Dementias I: Overview, Infections Presenting as Rapidly Progressive Dementia and Antibody-Mediated Rapidly Progressive Dementia

Thursday 04/26/18
01:00 PM - 03:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Seminar
Michael D. Geschwind, MD, PhD, FÂ鶹´«Ã½Ó³»­
Participants should be familiar with the differential diagnosis of prion and antibody-mediated causes of RPD and the clinical presentation and evaluation of the more common conditions.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Advanced Practice Provider
Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider
Case-based, Didactic, Audience Participation
Event Timeline
01:00 PM - 01:05 PM Luncheon Introduction
Michael D. Geschwind, MD, PhD, FÂ鶹´«Ã½Ó³»­
01:05 PM - 01:55 PM Speaker Infectious Causes of Rapidly Progressive Dementias
Allen J. Aksamit, Jr., MD, FÂ鶹´«Ã½Ó³»­
01:55 PM - 02:45 PM Speaker Assessment of Rapidly Progressive Dementias: Antibody-mediated Encephalopathies
Steven Vernino, MD, PhD, FÂ鶹´«Ã½Ó³»­
02:45 PM - 03:00 PM Q&A Questions and Answers
Faculty Disclosures
Michael D. Geschwind, MD, PhD, FÂ鶹´«Ã½Ó³»­ Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Steven Vernino, MD, PhD, FÂ鶹´«Ã½Ó³»­ Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for lundbeck. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regeneron. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alterity. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Autonomic Neuroscience (Elsevier). The institution of Dr. Vernino has received research support from Takeda. The institution of Dr. Vernino has received research support from NIH/NHLBI. The institution of Dr. Vernino has received research support from Lundbeck. The institution of Dr. Vernino has received research support from Regeneron.
Allen J. Aksamit, Jr., MD, FÂ鶹´«Ã½Ó³»­ Dr. Aksamit has nothing to disclose.